Liang Li
ORCID: 0000-0003-2424-4926Also affiliated with Nantong University, Peking University, Sichuan University, Affiliated Hospital of Nantong University, Key Laboratory of Guangdong Province, The First People’s Hospital of Lianyungang, Peking University First Hospital, Southern Medical University
Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Why this DataRank?
An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →Papers
Driven by 8 papers. Top paper: “FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome”.
Liang Li, Weishi Yuan, Stacy S. Shord, Lei Nie, Bahru A. Habtemariam +4 more
Ceng Zhang, Yi‐Te Lee, Benjamin V. Tran, Jing Wang, Hyo Yong Kim +49 more
Xiaolin Wang, Liangliang Bai, Guannan Tang, Kelly Carter, Ji Cui +16 more
Russell G. Rogers, Geoffrey de Couto, Jackelyn Valle, Liang Li, Ahmed Ibrahim +6 more
Alessandra Ciullo, Liang Li, Chang Li, Ashley Morris, Eduardo Marbán +2 more
Haixia Jiang, Siyao Yang, Chengcheng Li, Chuanjiang Li, Ruifan Shao +10 more
Sasha Smolgovsky, Liang Li, Lauren S. Kelly, Travis J. Antes, Kiel Peck +8 more
Chang Li, Liang Li, K. Candis Jones‐Ungerleider, Kiel Peck, Eduardo Marbán +2 more